Targeted drug combo tested for Tough-to-Treat lung cancer
NCT ID NCT04452877
Summary
This study tested the safety and effectiveness of two drugs, dabrafenib and trametinib, given together to Chinese patients with advanced non-small cell lung cancer that has a specific genetic change called BRAF V600E. The goal was to see if this combination could shrink tumors and control the cancer. About 40 patients received the treatment and were monitored to see how they responded and for any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Harbin, Heilongjiang, 150081, China
-
Novartis Investigative Site
Changsha, Hunan, 410013, China
-
Novartis Investigative Site
Chengdu, Sichuan, 610041, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310003, China
-
Novartis Investigative Site
Hangzhou, Zhejiang, 310022, China
-
Novartis Investigative Site
Beijing, 100036, China
-
Novartis Investigative Site
Guangzhou, 510060, China
-
Novartis Investigative Site
Shanghai, 200032, China
Conditions
Explore the condition pages connected to this study.